Risk Outlining and Uncertainty Contour for Quantification of Acyclovir Using LC-MS: Solicitation to in Vitro Cell Line Studies
 
More details
Hide details
1
Pharmacy Department, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara - 390001, Gujarat State, India
CORRESPONDING AUTHOR
Rajashree Mashru   

Pharmacy Department, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara - 390001, Gujarat State, India
Publication date: 2017-10-05
 
Eurasian J Anal Chem 2015;10(2):113–126
 
KEYWORDS
ABSTRACT
Outlining of risk profile and uncertainty estimation are the two chief and significant strictures that need to be adopted during the development of pharmaceutical process, to ensure reliable results. In this era, the conventional method validation agenda needs to be extemporized so as to certify extraordinary method reliability to measure quality attribute of a drug product. In this research work, risk sketch and expanded uncertainty in the analysis of acyclovir were studied. LC-MS method was validated in our laboratory as per ICH guidelines and risk profile has been outlined including uncertainty estimation using the cause-effect approach. In the course of validation, the calibration model found to be defensible when encountered with Levene’s and lack of fit test. The proposed research work evidently demonstrates the application of theoretical concepts of uncertainty and risk profile in the methods used for analysis in drug discovery process.
 
REFERENCES (32)
1.
Arnal J, Gonzalez-­‐Alvarez I, Bermejo M, Amidon G, Junginger H, Kopp S, Midha K Shah, V Stavchansky, S Dressman J (2008) Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir. Journal of pharmaceutical sciences 97: 5061-5073.
 
2.
Barwick V, Ellison SR (1999) Measurement uncertainty: Approaches to the evaluation of uncertainties associated with recovery†. Analyst 124: 981-990.
 
3.
Basavaiah K, Prameela H (2002) Simple spectrophotometric determination of acyclovir in bulk drug and formulations. Il Farmaco 57: 443-449.
 
4.
Basavaiah K, Prameela H, Chandrashekar U (2003) Simple high-performance liquid chromatographic method for the determination of acyclovir in pharmaceuticals. Il Farmaco 58: 1301-1306.
 
5.
Bertram GK (2001) Basic and clinical pharmacology. Editorial Mc Graw Hill.
 
6.
Biron KK, Elion GB (1980) In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrobial agents and chemotherapy 18: 443-447.
 
7.
Boulieu R, Gallant C, Silberstein N (1997) Determination of acyclovir in human plasma by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 693: 233-236.
 
8.
Brown SD, White CA, Chu CK, Bartlett MG (2002) Determination of acyclovir in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography. Journal of Chromatography B 772: 327-334.
 
9.
Daabees H (1998) The use of derivative spectrophotometry for the determination of acyclovir and diloxanide furoate in presence of impurity or degradation product. Analytical letters 31: 1509-1522.
 
10.
Diaconu I, Aboul-Enein HY, Bunaciu AA, Tănase IG (2010) Estimation of uncertainty for measuring codeine phosphate tablets formulation using UV-VIS spectrophotometry. Analytical letters 43: 1207-1216.
 
11.
Dubhashi S, Vavia P (2000) Stability indicating Reverse Phase HPLC method for Acyclovir. Indian drugs-Bombay 37: 464-468.
 
12.
Fujino H, Ueno I, Goya S (1993) Determination of amantadine by pre-labeling with 3-(7'-methoxycoumarin-3'-carbonyl)-benzoxazoline-2-thione and high-performance liquid chromatography with fluorescence detection. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan 113: 391-395.
 
13.
Hubert P, Nguyen-Huu JJ, Boulanger B, Chapuzet E, Cohen N, Compagnon PA, Dewé W, Feinberg M, Laurentie M, Mercier N (2007) Harmonization of strategies for the validation of quantitative analytical procedures: A SFSTP proposal–Part III. Journal of pharmaceutical and biomedical analysis 45: 82-96.
 
14.
International Conference on Harmonization, Q2B Validation of Analytical Procedures: Methodology, Consensus Guidelines, ICH Harmonized Tripartite Guidelines, 1996.
 
15.
International Conference on Harmonization, Q2A Validation of Analytical Procedures: Consensus Guidelines, ICH Harmonized Tripartite Guidelines, 1994.
 
16.
International organisation for standardization, ISO-IEC 17025:1999: General Requirements for the Competence of Testing and Calibrating Laboratories, ISO,Geneva,1999.
 
17.
Kishino S, Takekuma Y, Sugawara M, Shimamura T, Furukawa H, Todo S, Miyazaki K, (2002) Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. Journal of Chromatography B 780: 289-294.
 
18.
Leis HJ, Fauler G, Windischhofer W (2002) Quantitative analysis of memantine in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry. Journal of mass spectrometry 37: 477-480.
 
19.
Macka M, Borak J, Semenkova L, Popl M, Mikeš V (1993) Determination of Acyclovir in Blood Serum and Plasma by Micellar Liquid Chromatography with Fluorimetric Detection. Journal of Liquid Chromatography & Related Technologies 16: 2359-2386.
 
20.
Mahrous M, Abdel-Khalek M, Daabees H, Beltagy Y (1992) Use of differential spectrophotometry for determination of cytarabine and acyclovir in their dosage forms. Analytical letters 25: 1491-1501.
 
21.
Mittal K, Patadia R, Vora C, Mashru RC (2014) A newfangled study using risk silhouette and uncertainty approximation for quantification of acyclovir in diverse formulation. Journal of Pharmaceutical Analysis.
 
22.
Mittal K, Tanvi D, Ashutosh U, Rajashree M, Jai M, Arti RT Estimation of Uncertainty For Measuring Galanthamine Hydrobromide In Pharmaceutical Formulation Using Ultraviolet Spectrophotometry. Journal of Pharmaceutical Research no 12: 34-38.
 
23.
Polli JE, Abrahamsson BS, Lawrence XY, Amidon GL, Baldoni JM, Cook JA, Fackler P, Hartauer K, Johnston G, Krill SL (2008) Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. The AAPS journal 10: 373-379.
 
24.
Skoulika SG, Georgiou CA (2003) Rapid, noninvasive quantitative determination of acyclovir in pharmaceutical solid dosage forms through their poly (vinyl chloride) blister package by solid-state Fourier transform Raman spectroscopy. Applied spectroscopy 57: 407-412.
 
25.
Sultan M (2003) Spectrophotometric determination of acyclovir in some pharmaceutical formulations. Il Farmaco 57: 865-870.
 
26.
Swart K, Hundt H, Groenewald A (1994) Automated high-performance liquid chromatographic method for the determination of acyclovir in plasma. Journal of Chromatography A 663: 65-69.
 
27.
Sweetman S (2002) Martindale the Complete Drug Reference 33. sup. rd edition Pharmaceutical Press, London.
 
28.
Tadepalli SM, Quinn RP (1996) Scintillation proximity radioimmunoassay for the measurement of acyclovir. Journal of pharmaceutical and biomedical analysis 15: 157-163.
 
29.
Teshima D, Otsubo K, Yoshida T, Itoh Y, Oishi R (2003) A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high-­‐performance liquid chromatography. Biomedical Chromatography 17: 500-503.
 
30.
Ulrich JC, Shihomatsu HM, Hortellani MA, Sarkis J (2006) Estimate of uncertainty of measurement in the determination of methylmercury in fish samples by Fia-Cv-Aas, Xviii. Imeko World Congress metrology for a sustainable development September pp: 17-22.
 
31.
Van Der Horst F, Teeuwsen J, Holthuis J, Brinkman U (1990) High-performance liquid chromatographic determination of amantadine in urine after micelle-mediated pre-column derivatization with 1-fluoro-2, 4-dinitrobenzene. Journal of pharmaceutical and biomedical analysis 8: 799-804.
 
32.
Hung CV, Henning PA, Leung DT, Sacks SL (2002) Development and validation of a plasma assay for acyclovir using high-performance capillary electrophoresis with sample stacking. Journal of Chromatography B 772: 291-297.
 
eISSN:1306-3057